IgA Subclasses
Immunoglobulins (antibodies) are glycoproteins produced by plasma cells, essential for humoral immune responses. There are five primary immunoglobulin isotypes: IgG, IgM, IgA, IgE, and IgD. Among these, IgA constitutes approximately 10–15% of total immunoglobulins and is crucial for mucosal immunity. IgA occurs in two subclasses: IgA1 and IgA2, differing structurally and functionally.
IgA1 is the predominant subclass in systemic circulation, accounting for approximately 80% of total IgA. It is instrumental in systemic immune responses by binding antigens, forming immune complexes, and activating the alternative complement pathway. However, IgA1 has an extended hinge region, making it vulnerable to bacterial proteases. In contrast, IgA2 is predominantly found in mucosal secretions such as saliva, tears, colostrum, and gastrointestinal secretions. The shorter hinge region of IgA2 confers resistance against proteolytic cleavage by microbial enzymes, thereby enhancing mucosal protection against pathogens.
Abnormal IgA subclass levels are associated with various clinical conditions. Selective IgA deficiency (sIgAD) is characterized by low or absent IgA levels with normal IgG and IgM concentrations, predisposing individuals to recurrent infections, autoimmune conditions, and allergic reactions (including anaphylactic transfusion reactions). A general decline in immunoglobulins, including IgA, is observed in Common Variable Immunodeficiency (CVID).
Elevated levels of IgA1-containing immune complexes contribute to IgA nephropathy, a renal disorder characterized by hematuria, proteinuria, and progressive renal impairment. Autoantibodies of the IgA type are associated with gastrointestinal disorders such as celiac disease and inflammatory bowel disease (IBD).
Measurement of IgA subclasses is beneficial for differential diagnosis, disease classification, and monitoring related autoimmune, immunodeficiency, and proliferative disorders.
- Diagnosis and assessment of selective IgA deficiency (sIgAD)
- As an aid in the diagnosis and monitoring of IgA nephropathy
- Differential diagnosis and evaluation of gastrointestinal autoimmune diseases, including celiac disease and inflammatory bowel disease (IBD)
- Identification and monitoring of monoclonal gammopathies involving IgA (e.g., IgA multiple myeloma and IgA-MGUS)
Lower levels of IgA2 with normal IgA1:
- Indicates selective IgA2 deficiency, increasing susceptibility to recurrent mucosal and disseminated infections.
Higher IgA2 levels with normal IgA1:
- Suggestive of monoclonal proliferation of plasma cells producing monoclonal IgA2 (such as IgA multiple myeloma or MGUS-IgA).
Increased total IgA levels:
- Commonly observed in inflammatory conditions, chronic infections, allergies, and autoimmune diseases.
Decreased total IgA levels:
- Suggestive of selective IgA deficiency or common variable immunodeficiency (CVID).
| Total IgA – Age Group | Reference Range |
| 1–3.9 years | 5–194 mg/dL |
| 4–6.9 years | 16–210 mg/dL |
| 7–9.9 years | 27–227 mg/dL |
| 10–11.9 years | 35–241 mg/dL |
| 12–13.9 years | 43–252 mg/dL |
| 14–15.9 years | 50–263 mg/dL |
| 16–17.9 years | 57–274 mg/dL |
| ≥18 years | 85–499 mg/dL |
| IgA1 – Age Group | Reference Range |
| 1–3.9 years | 6–163 mg/dL |
| 4–6.9 years | 16–186 mg/dL |
| 7–9.9 years | 26–209 mg/dL |
| 10–11.9 years | 34–228 mg/dL |
| 12–13.9 years | 40–243 mg/dL |
| 14–15.9 years | 46–259 mg/dL |
| 16–17.9 years | 53–274 mg/dL |
| ≥18 years | 76–328 mg/dL |
| IgA2 – Age Group | Reference Range |
| 1–3.9 years | <0.5–12.4 mg/dL |
| 4–6.9 years | <0.5–25.7 mg/dL |
| 7–9.9 years | 1.5–38.9 mg/dL |
| 10–11.9 years | 2.9–49.9 mg/dL |
| 12–13.9 years | 4.0–58.7 mg/dL |
| 14–15.9 years | 5.2–67.5 mg/dL |
| 16–17.9 years | 6.3–76.3 mg/dL |
| ≥18 years | 6.9–114.3 mg/dL |
Serum (SST tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 30 days
- Kidney Int Rep. 2023 Mar 21;8(6):1151-1161. [PMID: 37284681]
- Monogr Allergy. 1986;19:277-301. [PMID: 3093850]
- J Clin Immunol. 2001 Sep;21(5):303-9. [PMID: 11720003]
- J Clin Immunol. 2000 Jan;20(1):77-82. [PMID: 10798611]
- J Clin Immunol. 2010 Jan;30(1):10-6. [PMID: 20101521]
- Nat Commun. 2020 Jan 8;11(1):120. [PMID: 31913287]
- Antibodies (Basel). 2019 Dec 5;8(4):57. [PMID: 7118169]